Cytokinetics Ownership | Who Owns Cytokinetics?

Overview Forecast RevenueFinancials Chart Transcripts

Cytokinetics Ownership Summary

Cytokinetics is owned by 60.45% institutional investors, 0.74% insiders, and 38.81% retail investors. T. rowe price investment management is the largest institutional shareholder, holding 15.97% of CYTK shares. Vanguard Health Care Inv is the top mutual fund, with 3.41% of its assets in Cytokinetics shares.

CYTK Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Cytokinetics	60.45%	0.74%	38.81%
Sector	Healthcare Stocks	232.51%	10.72%	-143.22%
Industry	Biotech Stocks	384.55%	10.58%	-295.13%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	19.08M	15.97%	$1.05B
Blackrock	14.67M	14.40%	$794.97M
Blackrock funding, inc. /de	16.40M	13.66%	$1.04B
Fmr	13.09M	10.96%	$719.52M
Vanguard group	12.05M	10.04%	$765.54M
Wellington management group llp	7.41M	6.20%	$407.17M
Tudor investment corp et al	6.00M	5.02%	$6.86M
State street	5.62M	4.70%	$308.73M
Deep track capital, lp	4.30M	3.60%	$236.33M
Geode capital management	3.06M	2.55%	$194.21M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rp management	980.39K	22.73%	$51.76M
Sarissa capital management lp	588.36K	17.93%	$32.34M
Foresite capital management iv	458.30K	13.79%	$25.19M
Deep track capital, lp	4.30M	6.60%	$236.33M
Boxer capital	2.10M	5.99%	$113.78M
Melqart asset management (uk)	783.77K	5.75%	$43.08M
Dafna capital management	394.94K	5.36%	$21.71M
Integral health asset management	1.40M	5.21%	$76.94M
Exome asset management	142.42K	4.74%	$7.83M
Catalio capital management, lp	451.58K	4.59%	$24.82M

Top Buyers

Holder	Shares	% Assets	Change
Tudor investment corp et al	6.00M	0.01%	6.00M
Blackrock	14.67M	0.02%	2.26M
Fmr	13.09M	0.04%	1.82M
T. rowe price investment management	19.08M	0.64%	1.48M
Woodline partners lp	1.65M	0.43%	1.44M

Top Sellers

Holder	Shares	% Assets	Change
Darwin global management	-	-	-4.58M
Vestal point capital, lp	725.00K	1.80%	-2.25M
Pfm health sciences, lp	-	-	-1.76M
Westfield capital management co lp	-	-	-1.31M
Hood river capital management	-	-	-1.26M

New Positions

Holder	Shares	% Assets	Change	Value
Tudor investment corp et al	6.00M	0.01%	6.00M	$6.86M
Norges bank	807.07K	0.01%	807.07K	$51.28M
Foresite capital management iv	458.30K	13.79%	458.30K	$25.19M
Affinity asset advisors	350.00K	1.68%	350.00K	$19.24M
Gsk	340.43K	2.71%	340.43K	$21.63M

Sold Out

Holder	Change
New england capital financial advisors	-1.00
Strategic advocates	-2.00
Financial gravity asset management	-2.00
Ameritas advisory services	-4.00
American capital advisory	-5.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	328	-22.64%	72,535,010	-48.66%	60	0.43%	182	-19.82%	87	-18.69%
Sep 30, 2025	403	16.47%	144,458,231	4.66%	120	0.91%	217	25.43%	105	-0.94%
Jun 30, 2025	344	-10.88%	137,969,518	1.88%	115	0.88%	171	-14.50%	106	-0.93%
Mar 31, 2025	25	-93.40%	16,158,180	-87.73%	13	0.11%	15	-91.28%	5	-96.09%
Dec 31, 2024	374	-5.32%	131,318,059	-2.91%	111	0.84%	166	-12.17%	128	29.29%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Health Care Inv	4.07M	3.41%	-
iShares Core S&P Mid-Cap ETF	3.89M	3.25%	-
Vanguard US Total Market Shares ETF	3.75M	3.15%	128.42K
Vanguard Total Stock Mkt Idx Inv	3.72M	3.11%	-77.64K
Vanguard Small Cap Index	2.90M	2.42%	-19.00K
iShares Russell 2000 ETF	2.81M	2.35%	-
T. Rowe Price Mid-Cap Growth	2.50M	2.09%	245.40K
T. Rowe Price Capital Appreciation	2.44M	2.04%	-556.00
T. Rowe Price US Mid-Cap Growth Equity	2.25M	1.88%	267.30K
T. Rowe Price Small-Cap Value	2.10M	1.75%	-4.81K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 05, 2026	Callos Andrew	EVP, Chief Commercial Officer	Sell	$928.95K
Feb 02, 2026	Callos Andrew	EVP, Chief Commercial Officer	Sell	$55.02K
Jan 05, 2026	Callos Andrew	EVP, Chief Commercial Officer	Sell	$904.20K
Jan 02, 2026	Callos Andrew	EVP, Chief Commercial Officer	Sell	$56.69K
Jan 02, 2026	Callos Andrew	EVP, Chief Commercial Officer	Sell	$55.90K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	5
2025 Q4	-	20
2025 Q3	-	15
2025 Q2	-	19
2025 Q1	-	22

CYTK Ownership FAQ

Who Owns Cytokinetics?

Cytokinetics shareholders are primarily institutional investors at 60.45%, followed by 0.74% insiders and 38.81% retail investors. The average institutional ownership in Cytokinetics's industry, Biotech Stocks , is 384.55%, which Cytokinetics falls below.

Who owns the most shares of Cytokinetics?

Cytokinetics’s largest shareholders are T. rowe price investment management (19.08M shares, 15.97%), Blackrock (14.67M shares, 14.40%), and Blackrock funding, inc. /de (16.4M shares, 13.66%). Together, they hold 44.03% of Cytokinetics’s total shares outstanding.

Does Blackrock own Cytokinetics?

Yes, BlackRock owns 14.40% of Cytokinetics, totaling 14.67M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 794.97M$. In the last quarter, BlackRock increased its holdings by 2.26M shares, a 18.19% change.

Who is Cytokinetics’s biggest shareholder by percentage of total assets invested?

Rp management is Cytokinetics’s biggest shareholder by percentage of total assets invested, with 22.73% of its assets in 980.39K Cytokinetics shares, valued at 51.76M$.

Who is the top mutual fund holder of Cytokinetics shares?

Vanguard Health Care Inv is the top mutual fund holder of Cytokinetics shares, with 3.41% of its total shares outstanding invested in 4.07M Cytokinetics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools